PLUS THERAPEUTICS Business Summary

Plus Therapeutics, Inc. (PSTV) is a clinical-stage pharmaceutical company specializing in the development and commercialization of targeted radiotherapeutics and precision diagnostics for rare, difficult-to-treat central nervous system (CNS) cancers. The company generates revenue through two primary segments: its proprietary CNSide diagnostic platform, which provides quantitative tumor cell analysis from cerebrospinal fluid, and its radiopharmaceutical pipeline, led by REYOBIQ (rhenium-186 obisbemeda). Revenue is currently driven by commercial diagnostic testing fees and significant non-dilutive grant funding from the NIH, CPRIT, and the U.S. Department of Defense. In the competitive landscape, Plus Therapeutics contends with radiopharmaceutical and medical technology firms such as Perspective Therapeutics, Nyxoah, and Nano-X Imaging. The company distinguishes itself by focusing specifically on the niche CNS market, utilizing a unique image-guided local beta radiation approach to deliver high-dose therapy directly to tumors while minimizing systemic toxicity. Leadership is spearheaded by President and CEO Dr. Marc H. Hedrick, a veteran executive and trained surgeon who previously co-founded StemSource, Inc. and led Cytori Therapeutics (the predecessor to Plus Therapeutics). The executive team includes VP and CFO Andrew Sims, a CPA with extensive experience in life sciences financial management, and EVP of Commercial Strategy Russ Havranek. The company’s strategic direction is further guided by Chairman Richard Hawkins, a seasoned life sciences entrepreneur and founder of Lumos Pharma. Notable institutional backing includes positions from The Vanguard Group, BlackRock, and Heights Capital Management, while the Board of Directors features industry experts like Dr. An van Es-Johansson and Robert Lenk, providing deep expertise in clinical development and regulatory affairs.